XML 74 R31.htm IDEA: XBRL DOCUMENT
v3.24.3

Revenue Recognition (Tables) | 9 Months Ended
--- | ---
Sep. 28, 2024
Revenue from Contract with Customer [Abstract] |
Schedule of Disaggregation of Revenue | The following is a summary of our net sales by category (in millions):
| Three Months Ended |  | Nine Months Ended
| September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
CSCA(1) |  |  |  |  |  |  |
Nutrition | $ | 127.1 |  |  | $ | 129.7 |  |  | $ | 303.8 |  |  | $ | 436.3 |
Upper Respiratory | 120.9 |  |  | 131.2 |  |  | 370.0 |  |  | 422.2 |
Digestive Health | 113.5 |  |  | 118.1 |  |  | 361.7 |  |  | 368.2 |
Pain and Sleep-Aids | 87.7 |  |  | 94.5 |  |  | 251.9 |  |  | 294.6 |
Healthy Lifestyle | 80.9 |  |  | 79.4 |  |  | 221.3 |  |  | 219.3 |
Oral Care | 66.9 |  |  | 76.7 |  |  | 204.8 |  |  | 235.5 |
Skin Care | 51.9 |  |  | 58.2 |  |  | 158.6 |  |  | 189.8 |
Women's Health | 18.0 |  |  | 10.5 |  |  | 62.0 |  |  | 35.6 |
Vitamins, Minerals, and Supplements ("VMS") | 3.5 |  |  | 4.4 |  |  | 13.0 |  |  | 13.9 |
Other CSCA | 0.9 |  |  | 0.8 |  |  | 2.4 |  |  | 2.5 |
Total CSCA | $ | 671.3 |  |  | $ | 703.5 |  |  | $ | 1,949.5 |  |  | $ | 2,217.9 |
CSCI |  |  |  |  |  |  |
Skin Care | $ | 91.0 |  |  | $ | 86.7 |  |  | $ | 333.5 |  |  | $ | 293.1 |
Upper Respiratory | 86.1 |  |  | 78.2 |  |  | 206.0 |  |  | 227.9 |
Pain and Sleep-Aids | 56.9 |  |  | 61.1 |  |  | 158.6 |  |  | 163.8 |
Healthy Lifestyle | 53.2 |  |  | 52.4 |  |  | 175.2 |  |  | 179.4 |
VMS | 43.0 |  |  | 46.1 |  |  | 127.4 |  |  | 135.4 |
Women's Health | 32.2 |  |  | 28.5 |  |  | 101.2 |  |  | 89.5 |
Oral Care | 23.3 |  |  | 24.8 |  |  | 75.0 |  |  | 75.5 |
Digestive Health | 9.0 |  |  | 10.8 |  |  | 27.0 |  |  | 30.0 |
Other CSCI(2) | 21.6 |  |  | 31.7 |  |  | 81.5 |  |  | 86.1 |
Total CSCI | 416.3 |  |  | 420.3 |  |  | 1,285.5 |  |  | 1,280.7 |
Total net sales | $ | 1,087.5 |  |  | $ | 1,123.8 |  |  | $ | 3,235.1 |  |  | $ | 3,498.7 |
(1) We updated our global reporting product categories as a result of legacy sales being moved out of Other CSCA and into respective categories. These product categories have been adjusted retroactively to reflect the changes and have no impact on historical financial position, results of operations, or cash flows. (2) Consists primarily of the Rare Diseases Business and other miscellaneous or otherwise uncategorized product lines and other adjustments, none of which is greater than 10% of the segment net sales. We generated net sales in the following geographic locations(1) (in millions):
| Three Months Ended |  | Nine Months Ended
| September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
U.S. | $ | 656.9 |  |  | $ | 690.3 |  |  | $ | 1,917.1 |  |  | $ | 2,176.3 |
Europe(2) | 397.3 |  |  | 399.8 |  |  | 1,225.5 |  |  | 1,232.6 |
All other countries(3) | 33.3 |  |  | 33.7 |  |  | 92.5 |  |  | 89.8 |
Total net sales | $ | 1,087.5 |  |  | $ | 1,123.8 |  |  | $ | 3,235.1 |  |  | $ | 3,498.7 |
(1) The net sales by geography are derived from the location of the entity that sells to a third party. (2) Includes Ireland net sales of $11.1 million and $26.8 million for the three and nine months ended September 28, 2024, and $11.9 million and $31.0 million for the three and nine months ended September 30, 2023. (3) Includes net sales generated primarily in Australia and Canada.
Schedule of Contract with Customer Balances | The following table provides information about contract assets from contracts with customers (in millions):
| Balance Sheet Location |  | September 28, 2024 |  | December 31, 2023
Short-term contract assets | Prepaid expenses and other current assets |  | $ | 27.4 |  |  | $ | 28.5 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration